Millions of Americans are now taking GLP-1 medications — drugs like Ozempic, Wegovy, Mounjaro, and Zepbound — to manage type 2 diabetes or support weight loss. If you or someone you love is among them, you may have seen recent headlines raising concerns about these medications and eye health. As a retinal specialist, I want to give you a clear, honest picture of what the research actually shows — because the headlines don’t always tell the whole story.
The short version: I believe, as most physicians do, that the benefits of GLP-1 medications generally almost always outweigh the risks for patients who need them. But there are real eye-related considerations worth understanding, and if you have diabetes, a retinal exam is something you should not skip.
What Are GLP-1 Medications?
GLP-1 receptor agonists are a class of medications that work by mimicking a hormone your body naturally produces after eating. They help regulate blood sugar, slow digestion, reduce appetite, and — in many patients — lead to significant weight loss. The most widely known include:
- Semaglutide — sold as Ozempic (for diabetes) and Wegovy (for weight management)
- Tirzepatide — sold as Mounjaro (for diabetes) and Zepbound (for weight management)
- Liraglutide — sold as Victoza and Saxenda
These drugs have been transformative for many patients across Oregon and the country. For people with type 2 diabetes, they can dramatically improve blood sugar control and reduce cardiovascular risk. For patients struggling with obesity, they can achieve weight loss results that were previously only possible with surgery.
So when researchers began reporting potential links to eye complications, it understandably raised concern. Let’s look at what the evidence actually says.
The Eye Conditions Being Studied
NAION: A Rare but Serious Concern
The condition that has generated the most headlines is something called non-arteritic anterior ischemic optic neuropathy, or NAION. It’s sometimes described as a “stroke of the optic nerve” — a sudden interruption of blood flow that can cause permanent vision loss, often in one eye.
A notable study published in JAMA Ophthalmology in 2024 by researchers at Mass General Brigham found that people with diabetes who were prescribed semaglutide were more than four times more likely to be diagnosed with NAION compared to those taking other diabetes medications. Among patients taking semaglutide for weight loss alone, the risk was even higher — more than seven times greater than comparison groups.
Those are numbers that deserve serious attention. However, context matters enormously here. NAION is already a rare condition — it affects roughly 1 in 10,000 people per year in the general population. Even with a multiplied relative risk, the absolute number of patients affected remains small. And importantly, the research does not yet establish a definitive cause-and-effect relationship. It is likely that the underlying conditions these patients have — diabetes, obesity, cardiovascular disease — are contributing factors independent of the medication itself.
The current guidance from the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society does not recommend that patients stop GLP-1 medications based on NAION risk alone. Instead, they emphasize shared decision-making between patient and physician based on individual circumstances.
It is worth noting that tirzepatide (Mounjaro, Zepbound) has not shown the same association with NAION in studies to date — an important distinction as the research continues to evolve.
Diabetic Retinopathy: The Rapid Change Effect
For patients with diabetes, there is a separate and well-established phenomenon worth understanding: rapid improvement in blood sugar can temporarily worsen diabetic retinopathy in the short term. This isn’t unique to GLP-1 medications — it has been observed with insulin therapy and other aggressive glucose-lowering approaches as well.
The mechanism is related to osmotic shifts in fluid as blood sugar drops quickly. The blood vessels in the retina, which have adapted over time to a high-glucose environment, can be stressed when that environment changes rapidly. In clinical trials, semaglutide was associated with a modestly higher rate of retinopathy complications compared to placebo — though the same studies showed fewer serious, sight-threatening retinal complications over time with use of these medications.
This is a nuance that’s easy to miss: short-term changes in retinal findings with better blood sugar control don’t necessarily mean long-term harm. In fact, the weight of evidence suggests that sustained, improved glycemic control — which GLP-1 medications help achieve — is protective of retinal health over the long run.
A Potential Benefit: Protection Against Macular Degeneration?
The story isn’t all about risk. Recent research presented at the American Academy of Ophthalmology’s annual meeting found evidence that GLP-1 drugs may actually reduce the risk of developing age-related macular degeneration (AMD) — both the wet and dry forms. AMD is one of the leading causes of vision loss in Oregon adults over 60, so this is a meaningful potential benefit that is still being actively studied.
My Perspective as a Retinal Specialist
I want to be straightforward with you: the research on GLP-1 medications and eye health is still evolving. New studies are being published regularly, and the picture will become clearer over the next few years.
What I can tell you is this — for the vast majority of patients who are appropriate candidates for these medications, the metabolic and cardiovascular benefits are substantial and well-established. Better-controlled diabetes means less long-term damage to the small blood vessels throughout the body, including those in the retina. Significant weight loss reduces systemic inflammation and cardiovascular risk. These are not small benefits. In many people, they are life-saving.
The potential eye-related risks, while real, are currently understood to be relatively rare and — critically — are manageable with appropriate monitoring. You and your prescribing physician are in the best position to weigh those factors based on your individual health history.
What You Should Do: The Importance of a Retinal Exam
Whether or not you are on a GLP-1 medication, if you have diabetes, a dilated retinal exam is one of the most important things you can do for your long-term vision. Diabetic retinopathy affects approximately 1 in 3 people with diabetes, and it often causes no symptoms in its early stages. By the time vision changes are noticeable, significant damage may already have occurred.
If you are starting or currently taking a GLP-1 medication and you have diabetes, here’s what I recommend:
- Get a baseline dilated retinal exam before starting the medication, or as soon as possible if you’ve already begun
- Schedule follow-up exams at least annually — or more frequently if your retina shows any early changes
- Report any new visual symptoms promptly: sudden blurry vision, dark spots, a gray area in your vision, flashes of light, or a curtain-like shadow across your field of view are all reasons to call your eye doctor right away
Even if you are taking a GLP-1 medication for weight loss and do not have diabetes, if you experience any sudden change in your vision, reach out to your prescribing physician and see a retinal specialist promptly.
Staying Informed
Patients throughout Oregon — from Eugene and Salem to Roseburg and communities along the Oregon Coast — are navigating these questions as GLP-1 medications become more widely prescribed. The science will continue to develop, and guidance may be refined as longer-term data becomes available.
The most important thing is to stay connected with your healthcare team, keep your scheduled eye appointments, and don’t ignore changes in your vision. These medications have helped millions of people — with careful monitoring, you can benefit from them while protecting your eye health at the same time.
Feel free to reach out to our office to schedule an appointment with me, Peter Karth, MD, MBA, FASRS, FACS, a trained retina specialist for your diabetic retina and eye issues. Call 541-873-8462.